ReviewJournal of nanobiotechnology2025
The potential of plant-derived vesicles in treating periodontitis and associated systemic diseases: current advances and future directions.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Plant-Derived Vesicle-like Nanoparticles for Cancer Therapy: From Drug Delivery to Combined Immunotherapy.Antioxidants (Basel, Switzerland) · 2026Review
- Plant-derived extracellular vesicles in skin and bone tissue engineering: current status, challenges, and future perspectives.Frontiers in bioengineering and biotechnology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPeriodontitis, a chronic multifactorial inflammatory disease, represents a significant public health burden among global chronic non-communicable diseases. In addition to affecting oral health, periodontitis is closely associated with a variety of systemic diseases. Current treatments, including surgical and nonsurgical therapies, lack clear superiority, underscoring the need for innovative therapeutic strategies. Plant-derived vesicles (PDVs), as natural products, have the advantages of being highly biocompatible, rich in biologically active components, and easy to cross biological barriers. Recent studies have shown that PDVs may treat periodontitis by maintaining oral microecological balance, remodeling the periodontal immune microenvironment, regulating inflammatory responses and oxidative stress, and promoting periodontal tissue regeneration. This review synthesizes the nomenclature based on MISEV 2023 and the latest research advances from biogenesis to removal, pre-processing, isolation, and characterization methods. It systematically evaluates potential applications of PDVs in periodontitis and associated systemic diseases, and presents the challenges facing current research.
conclusionPDVs hold promise as a novel, multitargeted approach for periodontitis and its systemic systemic diseases. However, overcoming limitations in production consistency, mechanistic understanding, and regulatory frameworks is critical to advancing their clinical application. Future research should prioritize interdisciplinary collaboration to harness PDVs' full therapeutic potential while addressing current translational barriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.